Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank57
3Y CAGR+110.8%
5Y CAGR-47.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+110.8%/yr
Annual compound
5Y CAGR
-47.1%/yr
Recent acceleration
Percentile
P57
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 20.48% |
| 2024 | 6.11% |
| 2023 | 18.04% |
| 2022 | 2.19% |
| 2021 | 121.57% |
| 2020 | 495.38% |
| 2019 | 250.94% |
| 2018 | 0.00% |